Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.

Lannfelt, L., Blennow, K., Zetterberg, H., Batsman, S., Ames, D., Harrison, J., Masters, C.L., Targum, S., Bush, A.I., Murdoch, R., Wilson, J., Ritchie, C.W., PBT2-201-EURO study group.
Journal   Lancet Neurol.
Species  
Analytes Measured   Abeta 40 , Abeta 42
Matrix Tested   Cerebrospinal fluid (CSF)
Year   2008
Volume   7
Page Numbers   779-86
Application   Alzheimers
Abstract
BACKGROUND: PBT2 is a metal-protein attenuating compound (MPAC) that affects the Cu2(+)-mediated and Zn2(+)-mediated toxic oligomerisation of Abeta seen in Alzheimer's disease (AD). Strong preclinical efficacy data and the completion of early, clinical safety studies have preceded this phase IIa study, the aim of which was to assess the effects of PBT2 on safety, efficacy, and biomarkers of AD.

METHODS: Between December 6, 2006, and September 21, 2007, community-dwelling patients over age 55 years were recruited to this 12-week, double-blind, randomised trial of PBT2. Patients were randomly allocated to receive 50 mg PBT2, 250 mg PBT2, or placebo. Inclusion criteria were early AD (mini-mental state examination [MMSE] score between 20 and 26 points or Alzheimer's disease assessment scale-cognitive subscale (ADAS-cog) score between 10 and 25 points), taking a stable dose of acetylcholinesterase inhibitor (donepezil, galantamine, or rivastigmine) for at least 4 months, a modified Hachinski score of 4 points or less, and CT or MRI results that were consistent with AD. The principal outcomes were safety and tolerability. Secondary outcomes were plasma and CSF biomarkers and cognition. Analysis was intention to treat. The trial is registered with ClinicalTrials.gov, number NCT00471211. FINDINGS: 78 patients were randomly assigned (29 to placebo, 20 to PBT2 50 mg, and 29 to PBT2 250 mg) and 74 (95%) completed the study. 42 (54%) patients had at least one treatment emergent adverse event (10 [50%] on PBT2 50 mg, 18 [62%] on PBT2 250 mg, and 14 [48%] on placebo). No serious adverse events were reported by patients on PBT2. Patients treated with PBT2 250 mg had a dose-dependent (p=0.023) and significant reduction in CSF Abeta(42) concentration compared with those treated with placebo (difference in least squares mean change from baseline was -56.0 pg/mL, 95% CI -101.5 to -11.0; p=0.006). PBT2 had no effect on plasma biomarkers of AD or serum Zn(2+) and Cu(2+) concentrations. Cognition testing included ADAS-cog, MMSE, and a neuropsychological test battery (NTB). Of these tests, two executive function component tests of the NTB showed significant improvement over placebo in the PBT2 250 mg group: category fluency test (2.8 words, 0.1 to 5.4; p=0.041) and trail making part B (-48.0 s, -83.0 to -13.0; p=0.009).

INTERPRETATION: The safety profile is favourable for the ongoing development of PBT2. The effect on putative biomarkers for AD in CSF but not in plasma is suggestive of a central effect of the drug on Abeta metabolism. Cognitive efficacy was restricted to two measures of executive function. Future trials that are larger and longer will establish if the effects of PBT2 on biomarkers and cognition that are reported here translate into clinical effectiveness.

View Publications

Related Products

R-PLEX Human Aβ42 (6E10) Antibody Set
Aβ42 (6E10) | Human
Singleplex
NEW
R-PLEX Human Aβ40 (6E10) Antibody Set
Aβ40 (6E10) | Human
Singleplex
NEW
Human (6E10) Aβ40 Ultra-Sensitive Kit
Aβ40 | Human
Singleplex
Human (6E10) Aβ42 Ultra-Sensitive Kit
Aβ42 | Human
Singleplex
V-PLEX Human Aβ42 Kit
Aβ42 | Human
Singleplex
V-PLEX Aβ Peptide Panel 1 (4G8) Kit
Aβ38, Aβ40, Aβ42 | Human, Mouse, Rat
Multiplex
V-PLEX Aβ Peptide Panel 1 (6E10) Kit
Aβ38, Aβ40, Aβ42 | Human
Multiplex
V-PLEX Aβ40 Peptide (4G8) Kit
Aβ40 | Human, Mouse, Rat
Singleplex
V-PLEX Aβ40 Peptide (6E10) Kit
Aβ40 | Human
Singleplex
V-PLEX Aβ42 Peptide (4G8) Kit
Aβ42 | Human, Mouse, Rat
Singleplex
V-PLEX Plus Aβ Peptide Panel 1 (4G8) Kit
Aβ38, Aβ40, Aβ42 | Human, Mouse, Rat
Multiplex
V-PLEX Plus Aβ Peptide Panel 1 (6E10) Kit
Aβ38, Aβ40, Aβ42 | Human
Multiplex
V-PLEX Plus Aβ40 Peptide (4G8) Kit
Aβ40 | Human, Mouse, Rat
Singleplex
V-PLEX Plus Aβ40 Peptide (6E10) Kit
Aβ40 | Human
Singleplex
V-PLEX Plus Aβ42 Peptide (4G8) Kit
Aβ42 | Human, Mouse, Rat
Singleplex
V-PLEX Plus Human Aβ42 Kit
Aβ42 | Human
Singleplex
Neurodegeneration Control Pack 1
Aβ38, Aβ40, Aβ42, Tau (total) | Human, Mouse, Rat
V-PLEX Aβ38 Peptide (6E10) Kit
Aβ38 | Human
Singleplex
V-PLEX Plus Aβ38 Peptide (6E10) Kit
Aβ38 | Human
Singleplex
Browse Our Products

By Analytes
By Applications
Search
Customer Service/Orders


Scientific/Technical Support


Instrument Support


Company Headquarters